Ossen Innovation Co Ltd (ADR) (OSN) Reaches $2.10 After 5.00% Gap Up, ENDONOVO THERAPEUTICS (ENDV) SI Decreased By 0.27%

ENDONOVO THERAPEUTICS INCORPORATED (OTCMKTS:ENDV) had a decrease of 0.27% in short interest. ENDV’s SI was 37,100 shares in April as released by FINRA. Its down 0.27% from 37,200 shares previously. About 2.09M shares traded. Endonovo Therapeutics Inc (OTCMKTS:ENDV) has declined 61.97% since September 9, 2016 and is downtrending. It has underperformed by 72.37% the S&P500.

The stock of Ossen Innovation Co Ltd (ADR) (NASDAQ:OSN) gapped up by $0.02 today and has $2.21 target or 5.00% above today’s $2.10 share price. The 8 months technical chart setup indicates low risk for the $41.10M company. The gap was reported on Apr, 18 by Barchart.com. If the $2.21 price target is reached, the company will be worth $2.06M more. About 16,891 shares traded. Ossen Innovation Co Ltd (ADR) (NASDAQ:OSN) has declined 10.82% since September 9, 2016 and is downtrending. It has underperformed by 21.22% the S&P500.

Analysts await Ossen Innovation Co Ltd (ADR) (NASDAQ:OSN) to report earnings on April, 20.

Ossen Innovation Co., Ltd. is a holding company. The company has market cap of $41.10 million. The Firm makes and sells an array of plain surface prestressed steel materials, and rare earth coated and zinc coated prestressed steel materials. It has a 1.81 P/E ratio. The Company’s materials are used in the construction of bridges, highways and other infrastructure projects in the People’s Republic of China and internationally.

Endonovo Therapeutics, Inc., formerly Hanover Portfolio Acquisitions, Inc., is a biotechnology firm developing a bioelectronic approach to regenerative medicine. The company has market cap of $6.11 million. The Firm operates through two divisions: intellectual property licensing and commercialization, and biomedical research and development, which includes development of its square wave form device. It currently has negative earnings. The Company’s Immunotronics platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and cell death.